Creating a new generation of small molecule protease inhibitors

Investors Overview

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

NASDAQ | KALV (Common Stock)
$7.07+0.09 (1.29%)
Stock chart for: KALV.O. Currently trading at $7.07 with a 52 week high of $20.02 and a 52 week low of $6.09.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources

Recent News

May 15, 2017KalVista Pharmaceuticals to Recognize HAE Day 2017

March 16, 2017KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

March 09, 2017KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical

More News

Upcoming Events

There are currently no events scheduled.

More Events

Featured Presentations

Download Documentation KalVista Corporate Presentation
Download Documentation Carbylan KalVista Conference Call (Audio File)
Download Documentation Carbylan KalVista Conference Call Transcript